112 related articles for article (PubMed ID: 18006181)
1. KL-6 and poor prognosis in NSCLC patients treated with gefitinib.
Ohara G; Kurishima K; Ishikawa H; Satoh H; Hizawa N
Lung Cancer; 2008 Jan; 59(1):138; author reply 139. PubMed ID: 18006181
[No Abstract] [Full Text] [Related]
2. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.
Fujiwara Y; Kiura K; Toyooka S; Hotta K; Tabata M; Takigawa N; Soh J; Tanimoto Y; Kanehiro A; Kato K; Date H; Tanimoto M
Lung Cancer; 2008 Jan; 59(1):81-7. PubMed ID: 17765355
[TBL] [Abstract][Full Text] [Related]
3. KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.
Kamiya K; Watanabe M; Kohno M; Izumi Y; Horinouchi H; Kawamura M; Shimada N; Nomori H
Respirology; 2011 Aug; 16(6):976-82. PubMed ID: 21651645
[TBL] [Abstract][Full Text] [Related]
4. Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.
Li J; Hu YM; Du YJ; Zhu LR; Qian H; Wu Y; Shi WL
BMC Cancer; 2014 Nov; 14():848. PubMed ID: 25410981
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib for refractory advanced non-small-cell lung cancer.
Moriguchi H; Kim TY; Sato C
Lancet; 2006 Jan; 367(9507):299-300. PubMed ID: 16443032
[No Abstract] [Full Text] [Related]
6. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Ishikawa N; Hattori N; Yokoyama A; Tanaka S; Nishino R; Yoshioka K; Ohshimo S; Fujitaka K; Ohnishi H; Hamada H; Arihiro K; Kohno N
Int J Cancer; 2008 Jun; 122(11):2612-20. PubMed ID: 18324627
[TBL] [Abstract][Full Text] [Related]
7. Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
Belani CP; Ramalingam S
Clin Lung Cancer; 2005 Jan; 6(4):203-4. PubMed ID: 15694010
[No Abstract] [Full Text] [Related]
8. Three-year survival in metastatic non-small cell lung cancer treated with gefitinib.
Costa DB; Schumer ST
Lung Cancer; 2006 Jul; 53(1):123-4. PubMed ID: 16723171
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer.
Wang MZ; Li LY; Wang SL; Zhang XT; Zhong W; Zhang L
Chin Med J (Engl); 2006 Jan; 119(1):63-8. PubMed ID: 16454984
[No Abstract] [Full Text] [Related]
10. Gefitinib plus docetaxel in non-small-cell lung cancer.
Singh N; Aggarwal AN
Lancet; 2009 Feb; 373(9663):541-2; author reply 542. PubMed ID: 19217980
[No Abstract] [Full Text] [Related]
11. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
Johnson DH; Arteaga CL
J Clin Oncol; 2003 Jun; 21(12):2227-9. PubMed ID: 12748243
[No Abstract] [Full Text] [Related]
12. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.
Ishikawa N; Daigo Y; Takano A; Taniwaki M; Kato T; Hayama S; Murakami H; Takeshima Y; Inai K; Nishimura H; Tsuchiya E; Kohno N; Nakamura Y
Cancer Res; 2005 Oct; 65(20):9176-84. PubMed ID: 16230376
[TBL] [Abstract][Full Text] [Related]
13. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Comis RL
Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
[No Abstract] [Full Text] [Related]
14. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib plus docetaxel in non-small-cell lung cancer.
Zalcman G; Bergot E
Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217981
[No Abstract] [Full Text] [Related]
16. Gefitinib plus docetaxel in non-small-cell lung cancer.
Costa DB; Kobayashi S
Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
[No Abstract] [Full Text] [Related]
17. Gefitinib versus docetaxel for previously treated NSCLC--letter.
Tassinari D; Lazzari-Agli L; Tombesi P; Sartori S
Clin Cancer Res; 2011 Jul; 17(13):4610; author reply 4611. PubMed ID: 21712456
[No Abstract] [Full Text] [Related]
18. Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment.
Park MJ; Lee J; Hong JY; Choi MK; Yi JH; Lee SJ; Oh SJ; Ahn JS; Park K; Ahn MJ
Cancer; 2009 Apr; 115(7):1518-30. PubMed ID: 19177485
[TBL] [Abstract][Full Text] [Related]
19. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
Okamoto T; Nakamura T; Ikeda J; Maruyama R; Shoji F; Miyake T; Wataya H; Ichinose Y
Eur J Cancer; 2005 Jun; 41(9):1286-90. PubMed ID: 15939264
[TBL] [Abstract][Full Text] [Related]
20. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
